Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

July 29, 2021

NASDAQ US Health Care Biotechnology earnings 44 min

Earnings Call Speaker Segments

Jessica Rennekamp

executive
#1

Operator, thank you. Good morning, everyone, and hello. We're glad you could be part of Agios's conference call for the second quarter of 2021. You can access the slides for today's call in the Investors section on agios.com, our website. With me today to deliver prepared remarks are our Chief Executive Officer, Dr. Jackie Fouse; our Chief Medical Officer, Dr. Chris Bowden; our Chief Commercial Officer, Darrin Miles; Jonathan Biller, our Chief Financial Officer and Head of Legal and Corporate Affairs; and for the Q&A portion, our Chief Scientific Officer, Dr. Bruce Car, will be joining. Prior to starting, I'd like to remind all of you that certain statements made during this call will contain forward-looking statements. There's a chance that real outcomes and figures might end up being quite different from anything suggested or implied by statements looking ahead, because of a range of hazards, unknowns, and additional elements — among them the ones described in our latest submissions to the SEC, along with any subsequent documents we might file with that agency. Having said that, I'll now hand things over to Jackie.

Jacqualyn Fouse

executive
#2

Thank you, Jesse. Hello, everyone, and I appreciate you being with us for our Q2 2021 earnings discussion. We're happy to share news of yet another period of solid advancement at Agios—our initial complete quarter following the completion of the transaction selling our oncology division to Servier. Our team is concentrated, motivated, and enthusiastic about what lies ahead as we keep moving our pipeline forward in genetically defined diseases, with mitapivat leading the way across its 3 first indications in hemolytic anemias. We've hit important milestones lately, filing our NDA for mitapivat in adults who have Pyruvate kinase deficiency during June, and also submitting our MAA to the EMA that same month. We're eager to collaborate with the FDA and EMA while they finish their evaluations. Through these 2 submissions, we've moved 1 step nearer to providing the first potentially disease-modifying treatment for individuals living with Pyruvate kinase deficiency. Robust Phase III findings from the ACTIVATE and ACTIVATE-T studies form the foundation for these regulatory filings. Complete data from each were shared not long ago at the European Hematology Association, or EHA Virtual Congress, in June. Our work preparing to commercialize mitapivat for PK deficiency has kept moving forward, and we're still on schedule for expected approval and launch during 2022; furthermore, we want to congratulate the Pyruvate Kinase Deficiency Foundation along with the Thrive with Pyruvate Kinase Deficiency Organization, as both recently began operations as the first 2 advocacy groups based in the U.S. focused specifically on PK deficiency. Both groups are led by patients, and it's truly thrilling to witness how this community has come together and the traction they're building in boosting awareness and speaking up for those affected by this condition. Past PK deficiency, we're likewise achieving great strides with late-stage development of mitapivat for thalassemia and sickle cell disease. At EHA, we shared favorable findings from our Phase II open-label trial of mitapivat involving adults with nontransfusion-dependent alpha or beta thalassemia. This evidence further confirms the promise of PK activation as a completely novel approach to managing thalassemia and constitutes the initial clinical information gathered from alpha thalassemia patients. We're still on schedule to kick off our 2 registrational Phase III studies, ENERGIZE and ENERGIZE-T, in not regularly transfused and regularly transfused adults with thalassemia, respectively, during this year. For sickle cell disease, we're also still on track to begin a pivotal Phase II/III study of mitapivat before the year ends. Past mitapivat, we're leveraging our knowledge in PK activation and cellular metabolism while pushing forward our earlier-stage research efforts in genetically defined diseases to set us up for lasting growth and momentum; during the fourth quarter, we intend to hold an Investor Day to provide additional details regarding our commercial launch strategy for mitapivat and PK deficiency and discuss our research and development pipeline more thoroughly. Before handing things over to Chris for an update on where our clinical development programs stand, I'd like to take a moment to let everyone know that Chris has made the decision to step away from his position as Chief Medical Officer at Agios, following a wonderful 7 years as a member of our leadership team. Once a transition period with his successor has played out over the months ahead, I'm delighted that Chris is going to stay with us in the capacity of strategic adviser through at least the close of 2022. We're happy for him as he embarks on this new chapter of his life, and we want to express our thanks for his leadership and his many years of service at Agios. Among the many things he accomplished and contributed, he supervised the building of our medical and clinical development organizations, served as Agios' lead medical representative both internally and externally, steered complicated regulatory interactions so that important drugs could reach patients, and was instrumental in how our organization and culture evolved. He has been a vital member of our team, and his efforts will keep touching the lives of patients for many years ahead. On behalf of all of us at Agios, I wish Chris every success going forward. I'm just as excited to share that Dr. Sarah Gheuens, who until now has been our Head of Clinical Development for genetically defined diseases, will take on the Chief Medical Officer role effective September 1. Sarah has spent almost 2 years at Agios and throughout her time here has been a leader who makes an impact and brings energy across the organization. Among Sarah's most significant accomplishments at Agios. She was central to the work tied to the PK deficiency filings as well as the design and strategy behind our sickle cell disease pivotal programs. She understands every aspect of our programs thoroughly and truly has a passion for serving people with genetically defined diseases. Before joining Agios, Sarah took on positions of growing responsibility at Biogen in safety and risk management, medical affairs and clinical development, and by training she is a urologist; we're eager to keep seeing great things from her as she steps into this new level of responsibility. With that, I'll now hand the call over to Chris.

Chris Bowden

executive
#3

Appreciate that, Jackie. Just like Jackie mentioned, we're extremely excited about the impact we can have on individuals dealing with genetically caused illnesses. During the last quarter, Agios and everyone touched by PK deficiency reached important milestones, because we filed for mitapivat's approval with regulators in both the U.S. and the EU. We're glad to share that our MAA passed validation, which kicked off the MAA review; regarding the NDA, the FDA has 60 days after submission to determine whether to accept the application. So we expect to get their response around the middle of August. If the application gets the green light, if mitapivat is granted priority review, and what the PDUFA date turns out to be — the agency will let us know all of that when the time comes. Taking everything together, we're very pleased with our progress and sense genuine momentum as we head into a packed second half of 2021. During EHA, we presented the full dataset from the Phase III ACTIVATE and ACTIVATE-T studies, which evaluated mitapivat in adults with PK deficiency — the former in patients who don't receive regular transfusions, the latter in those who do. Primary and secondary endpoints were achieved in both studies, and that includes patient-reported outcomes addressing symptom burden as well as how PK deficiency affects quality of life. When it comes to mitapivat, tolerance is generally good, and across both studies the safety data lined up with what had already been published. At our EHA investor event, Dr. Andreas Glenthøj also spoke, emphasizing how profoundly PK deficiency affects patients' quality of life, the gaps in the current treatment options for the condition, and the possibility that mitapivat could become the first therapy able to modify the disease for these patients. Now on to thalassemia: at EHA we additionally shared findings covering all 20 participants during the core period of our Phase II trial evaluating mitapivat in nontransfusion-dependent alpha and beta thalassemia. As we had indicated in our earlier proof-of-concept findings, the trial achieved its main goal, since 16 out of 20 participants saw their hemoglobin rise by at least 1 gram per deciliter compared with where they started, as measured at one or more points between weeks 4 and 12. Beyond that, among individuals with either alpha or beta thalassemia who received mitapivat, we saw a durable hemoglobin response along with gains in hemolysis and ineffective erythropoiesis. Mitapivat's tolerability was good as well, and its safety profile matched what earlier studies showed. In our view, these outcomes highlight how mitapivat could substantially address key features of thalassemia, such as hemolysis and ineffective erythropoiesis. Another development we're enthusiastic about is that alpha thalassemia has yielded data for the very first time, showing hemoglobin rising above baseline levels across every one of the 5 patients in that subgroup. Regarding mitapivat for thalassemia, our 2 worldwide placebo-controlled pivotal studies — ENERGIZE and ENERGIZE-T — remain scheduled to begin within this year, while we keep working through global submissions of the protocols and get locations ready to enroll participants. Moving now to sickle cell disease, we continue to expect our pivotal Phase II/III clinical trial to launch before this year ends. For sickle cell disease, the mitapivat Phase II/III trial is going to enroll patients aged 16 or above who experienced 2 to 10 sickle cell crises within the last 12 months and whose hemoglobin falls between 5.5 and 10.5 grams per deciliter at screening. In Phase II, 69 patients will be randomized in a 1:1:1 ratio to receive either 50 milligrams of mitapivat twice daily, 100 milligrams of mitapivat twice daily, or matching placebo. The primary endpoint is hemoglobin response, which is defined as a change of at least 1 gram per deciliter from baseline at week 12. Those data are going to help us establish a clear dosing approach for the Phase III part. Once we've completed our review of the Phase II data, we'll move into Phase III, where 198 patients will be assigned randomly, in a 2:1 fashion, to receive either placebo or whichever dose of mitapivat was selected during Phase II. This trial has two primary endpoints. The first one looks at hemoglobin response — that means an improvement from baseline of at least 1 gram per deciliter when we reach week 52. The second endpoint involves lowering the yearly rate at which sickle cell pain crises occur. In our view, structuring the program as Phase II/III like this lowers the risk mitapivat faces on the road to approval in this challenging disease, and it raises the likelihood that we end up with a label covering a broad indication. Additionally, our work with the NIH and University of Utrecht continues on their trials of mitapivat for sickle cell disease. Findings from each of those trials should be turned in for presentation at ASH this December. At the NIH, the core study — which enrolled 17 patients — has completed enrollment, according to Dr. Chen, while the extension study is still bringing in patients. The data sets that will be shown at ASH ought to provide us with further efficacy, safety, and translational information to back mitapivat's clinical development in sickle cell disease patients. Beyond mitapivat, we're advancing AG-946, our next-generation PKR activator, into a Phase I trial involving healthy volunteers. That study began accepting patients in the prior year, and we intend to present findings at ASH. Insights gained from reviewing the complete set of AG-946 healthy volunteer results will shape how we proceed with developing this molecule clinically. At our investor event in the fall, we'll share more specifics regarding the research and development pipeline. Prior to passing the discussion to Darrin for a review of our commercial efforts, I'd like to express my gratitude to each of my Agios teammates for the opportunity to have worked with you over these last 7 years. The experience has been deeply fulfilling and enjoyable, and the results clearly demonstrate what we've achieved. My successor, Sarah Gheuens, is ready to lead our team toward even greater accomplishments, and I am excited to watch the Agios story keep unfolding. Darrin?

Darrin Miles

executive
#4

Thanks, Chris. Preparations for the commercial rollout of mitapivat in PK deficiency keep moving ahead nicely. Every piece of our customer-facing and patient support organization, including the people and the systems, is now staffed and has completed training. Our field organization, made up of sales reps along with credentialed nurse clinical educators, is at this point working hand in hand with physicians who may be treating PK deficiency patients throughout the United States, concentrating on account profiling, building disease awareness, and carrying out patient support and profiling initiatives via disease education. One key part of what they do involves teaching physicians about Anemia ID, the genetic testing service sponsored by Agios. With requests for test kits now comfortably past 1,000, we anticipate Anemia ID will grow into an ever more vital program that helps patients pursuing a definitive diagnosis for their hemolytic anemia while also speeding up our efforts to profile PK deficiency patients. According to our latest market research, 70% of physicians who responded routinely order further diagnostic testing for patients who have hemolytic anemias of unknown etiology. That finding matters, since it bodes well for future uptake of genetic testing to accurately diagnose hemolytic anemias, PK deficiency among them. The Anemia ID program has drawn a highly enthusiastic response. Moreover, physicians in our research said they lean toward testing a substantial share of their patients with hemolytic anemia of unknown etiology, citing both the range of mutations covered by the panel and how comparatively simple it is to use; back in June we also introduced the revamped myAgios patient support service, meant for individuals living with PK deficiency as well as those who care for them, drawing on what we learned and a good deal of the technical infrastructure behind the oncology myAgios program, while folding in perspectives from PK efficacy patients and clinicians so the result is a tailored program built around this community's particular needs. Patients and caregivers who enroll get matched with a dedicated patient support manager who is clinically trained, delivering continuing personalized support, educational materials, and chances to engage with fellow patients and caregivers within the PK deficiency community. Alongside other educational initiatives, our field team is teaching physicians and their staff about the service's availability and the ways they can help patients sign up. After we disclosed the ACTIVATE and ACTIVATE-T results at EHA in June, we ran fresh market research to refresh what we know about general physicians' awareness and comprehension of PK deficiency and what that could mean for disease management, presuming mitapivat gets approved next year. We discovered that awareness measures for PK deficiency have risen compared with the identical stretch in 2020, since 85% of academic and community physician respondents are now familiar with PK deficiency. What's more, over half of them reported managing 1 to 2 patients previously diagnosed with PK deficiency; that's encouraging, as it shows physicians are getting better at identifying and diagnosing PK deficiency, and we plan to keep backing that with further educational activities in the months before approval in 2022. Additionally, our market research points to something else: given how they interpret the Phase III results, a large number of doctors are likely to think about putting mitapivat to use for PK-deficiency individuals across varying degrees of disease severity — that includes factors like hemoglobin level and transfusion history. That said, decisions about prescribing will rest on each patient's own history, presentation, and the parameters laid out in the approved label for mitapivat. These reactions give us encouragement, as does the broader rise in how well physicians grasp the burden of this disease. On the whole, we're quite happy with how far we've come on launch preparations in every function here at Agios, and with the way the treatment community has responded to our wide-ranging disease education work; with our field team now at full strength, we anticipate this picking up speed over the next few months, and there's excitement about what we can accomplish for patients, with growth tied to the ACTIVATE disclosures. With that, I'll hand things to Jonathan so he can walk through the second quarter financials.

Jonathan Biller

executive
#5

Appreciate that, Darrin. You can find our Q2 2021 financial results in the press release that went out this morning, and I'll walk through them. Additional detail will be in the 10-Q we file later today. Just to remind everyone, when we discuss second quarter financial results, we're only covering continuing operations on a comparative basis, so the divested oncology business is left out. R&D came in at $62 million for the second quarter, up $7.9 million from the same period in 2020. That year-over-year rise in R&D was mainly due to start-up costs tied to the Phase III studies of mitapivat in thalassemia and sickle cell disease, plus the filing of our NDA and MAA for mitapivat in PK deficiency, along with our launch preparation efforts. SG&A expenses totaled $29.2 million in the second quarter, basically level with what we saw in the second quarter of 2020. We also booked $2 million in TIBSOVO royalty income during the second quarter of 2021, which sits within the gain on sale of oncology business line item on our income statement; we closed the quarter with roughly $1.7 billion in cash, cash equivalents and marketable securities. Given that cash balance, we believe we can carry out our current operating plan through major catalysts and reach cash flow positivity without raising additional equity. During Q2, we completed $529 million of the up to $1.2 billion in share repurchases our Board of Directors authorized, including the shares we acquired from Bristol-Myers Squibb. To be specific, we bought back slightly fewer than 10.5 million shares at an average price of $50.41, which cut our total shares outstanding by about 15%, leaving us at 59.9 million shares at the end of the quarter. As we've said before, the 10b5 to 1 plan we adopted early in Q2 allows for up to roughly $415 million in further share repurchases through year-end. How much more we actually repurchase through year-end will hinge on how volatile our share price is during that stretch. Operator, please open the line for questions.

Alethia Young

analyst
#6

Congratulations on everything that's been achieved. I'd like to spend a moment discussing mitapivat, and perhaps, since you're engaged in educating people about patient support, how often are these individuals typically seeing their doctors? And what sort of outreach and work is required in that regard? Or is it more a matter of a structural warehousing effect? Or is it genuinely work that had to be done to get these people back into care?

Darrin Miles

executive
#7

Alethia, it's Darrin here. Getting patients to return isn't necessarily going to be the problem, because they're typically under — for those who've received a diagnosis and clearly are connected to a physician, they're under some form of monitoring plan, correct? Patients whose disease is more severe will be seeing their doctors on a more regular basis; those whose disease is less severe will have somewhat longer — generally there will be a longer interval separating their doctor visits. But keep in mind, their iron load is still being monitored, their hemoglobin is still being monitored. So how often physician visits occur isn't necessarily where we want to — where our focus would go. What we're doing at present, I believe, is concentrating on patient profiling, identification, and education of physicians and patients about the disease. And that, I believe, is where our efforts need to keep being concentrated, even after launch. The relationship between physician and patient ought to be fine, and there's no need for us to — nothing there requires us to delve into it. We simply must ensure they're aware; and after that's accomplished, I believe everything else follows from it.

Kennen MacKay

analyst
#8

To begin with, Chris, I was sorry to learn you're leaving, though I look forward to getting acquainted with Sarah, who's taking your place. It's also good to know you'll remain through next year to help with the handover. Perhaps a brief question regarding the regulatory filings for mitapivat: which part of the FDA are you dealing with on those submissions in PKD — the hematology group or the rare disease group?

Chris Bowden

executive
#9

Kennen, Chris here. The FDA groups we're collaborating with fall under the cardiology, renal, and the oncology, hematology divisions. The submission as such sits within the cardiology renal; so it's actually an unusual arrangement, since the individuals who've been most engaged with us and are most active on the submission belong to the hematology division.

Kennen MacKay

analyst
#10

That's pretty much what I intended to ask next, and I was simply curious about how things have gone in terms of the back-and-forth so far — is that division basically caught up when it comes to rare diseases and PKD? Or how would you describe the interactions up to this point?

Chris Bowden

executive
#11

The team, the group at FDA we've been dealing with, has been involved with this program for — they've been giving us advice and engaging with us ever since I came to the company. So they know this disease very well, along with the particular demands involved when you're dealing with a rare disease population; so that doesn't worry me at all; and I'd say the consistency — and I think what matters is that, over the years, as you've heard us discuss the guidance and the reasons we built the trials the way we did, trying to give them all the data they'll require to reach a decision so we can show clinical benefit, it's been the same set of people

Anupam Rama

analyst
#12

Maybe I can ask something more strategic. A lot of us on the sell side, I believe, build in a price reduction for mitapivat over a longer horizon because of the SCD indication. In your estimation, what level of peak sales for SCD would mitapivat need to hit for a price cut to be justified, rather than, for instance, getting the most value out of the product by maintaining ultra-orphan pricing?

Chris Bowden

executive
#13

Discussing what peak sales in sickle cell might look like would be premature. What I can say is that this would mean assuming you simply wanted to at minimum break even, correct, as you go from the first 2 indications into sickle cell, and then you factor in a cut. Based on our thinking, achieving that would need only under 4%, 3% share of that market to at least break even over the entire program. So not a great deal is needed, since sickle cell's size is substantial enough to let you absorb that cut. That's the reason we're so bullish on the added value, right, that we could capture once we enter sickle cell even with competition.

Jacqualyn Fouse

executive
#14

This is Jackie, and I want to quickly chime in here. Like we've mentioned on numerous occasions — and I believe both Chris and Darrin have frequently brought this up — those pricing choices will be made by looking at the full picture of clinical data available to us at that moment, along with the product profile, naturally. So as you might expect, there's quite a bit involved when you factor in things like hemoglobin increase, VOC reduction, every secondary endpoint, the patient reported outcomes, and everything along those lines. So there are many considerations that go into making that pricing call at some future point.

Elizabeth Webster

analyst
#15

This is Elizabeth, filling in for Salveen. Would you mind reminding us whether you plan to launch mitapivat and PKD at the same time in both the U.S. and EU? And since you're kind of talking about this at your Investor Day in 4Q, maybe you could comment on how the launch team is structured and how big it is, plus your progress when it comes to finding more patients — and how many PKD patients have been identified so far?

Darrin Miles

executive
#16

Got it. Okay, this is Darrin. That's a lot to cover, so let me try to work through it. I'll take the structure question first. As I said during our prepared comments earlier, we've completely filled our internal and external teams, correct? That's roughly just under 20 representatives — sales reps, plus a small group of nurse educators who will work alongside them, and that's the U.S. team. When it comes to the EU — as we've said before, we already have people on the ground there, right? We've got an MSL team in place, and we also have a small set of experts who are dedicated to building awareness and growing, or pushing forward, our patient profiling work across each of the major EU markets. And we keep at that work, especially the critical path activities, to make sure we can launch mitapivat in the EU shortly after approval; but we've also said that we're looking at a number of options, right, weighing the chance to work with a partner that already has a footprint in the EU and hopefully beyond — outside the EU, given how much value for mitapivat extends — patient value that extends past the major markets that could overlay mitapivat or bring mitapivat into their current infrastructure. That's where our efforts have been concentrated. So the thinking is to keep things moving so a launch is possible, especially in Germany, where you can launch right away with adequate repricing. And then — but also to be able to hand that work over to a potential partner once we find the kind of deal that we feel fairly reflects the value mitapivat will deliver.

Elizabeth Webster

analyst
#17

Great. And then maybe you could tell us what you think about the work going into finding patients and how many have been identified so far.

Darrin Miles

executive
#18

Yes, yes. Yes, so we continue doing the work behind our patient profiling efforts, right, which means locating additional patients; as we've mentioned previously, we've identified approximately 1,000 patients throughout the U.S. and the EU. That includes pediatric patients, those enrolled in our various clinical programs, along with incidental patients we come across while interacting with physicians. It's an important figure that I'm aware everybody wants to hear increasing detail about, but — and we do keep close track of it. That's not the area I'd concentrate on, though. Particularly since the U.S. launch is getting nearer, the key thing is being able to take every patient who gets flagged to us and link them up — correct? We don't have their personal details or anything that identifies them. Even so, you need to connect that person with a specific doctor, confirm they actually go through testing, and find out whether that doctor would want to rely on Anemia ID for additional diagnostic confirmation. On top of that, we rolled out our patient support program just within the past month. And if everything goes according to plan, those doctors would start to recognize the benefit of sending their patients our way into these programs. That gives you a clearer picture of the total confirmed patient population we're dealing with here in the U.S. So this is exactly where our attention is going, correct? We keep pushing the diagnostic differential forward, making sure those patients receive the right support, and providing the education that myAgios is able to offer — which will carry us right up to and all the way through the approval.

Kelsey Goodwin

analyst
#19

Kelsey Goodwin here, filling in for Michael. Perhaps we can pick up where that left off a little. Looking ahead, as you keep pushing these efforts, how do you expect the rate and slope of PKD diagnosis to develop? What sort of assumptions are you factoring in for this launch, both near term and long term?

Darrin Miles

executive
#20

Yeah. We've got some signals from what we saw with Anemia ID, which is still early. And some signals from the Spanish IST, the screening IST, which reported that roughly — I believe around 20% of those hemolytic anemia patients who were screened ended up being diagnosed with PKD; that gives us a solid feel for what your diagnosis rate could turn out to be among the patients who get tested, especially those who have — who are diagnosed with hemolytic anemia of unknown etiology. On that point I'm less — the launch ramp doesn't worry me there, because I think we keep — we're doing all the things we need to do to make testing easier. I expect we'll see that speed up now that we've got a full contingent in the field helping educate practices, plus our myAgios support educating patients. What I am — what remains outstanding in my mind, and I think our focus is on understanding better, is how the access profile will shape up, especially during those first 6 to 9 months of launch, right, where we know that with a number of payers, there's going to be a new-to-market block that means physicians have to seek medical exception. And that will then stretch out the time between diagnosis and when you ultimately — when the patient can ultimately get the treatment. So the demand, and our recent quantitative work confirmed this, the demand is going to be there. So we have the desire to treat broadly for these patients. We've got all the programs in place like Anemia ID, the work we shared with you last time on 23andMe, to help boost overall awareness, drive support for patients, and give them better testing options. And then — so the script, the chance for the patient to receive the treatment, I think, is going to be high. The question is whether there's enough time in those first months for physicians to work through the access challenges.

Mark Breidenbach

analyst
#21

Nice to see the momentum building. Chris, naturally, we hate to lose you too. About that pivotal sickle cell trial — could you walk us through the biggest remaining hurdles that have to be cleared before it can get underway? Also, on the academic sickle cell studies, with readouts possibly coming later in the year, can you tell us roughly how many patients the Utrecht trial should give us? And give us a quick refresher on how that study mainly differs from the NIH one.

Chris Bowden

executive
#22

Sure, this is Chris. When it comes to kicking off any of the Phase III — the thalassemia Phase II/III program, those global trials — the protocols are done and locked, and what's left is the heavy operational lift. That means a long list of tasks involving regulators, trial sites, and CROs. Beyond the protocol itself, you've got all the logistics of standing up your IVRS, meaning the randomization systems, plus getting every translational medicine lab assay in place, and figuring out how all of it flows together. It's a really complex web of work, and while some of it can move forward — a lot of it happens concurrently. But in every country, and at every site within every country, you're dealing with contracts and working through countless steps. There are too many to list, though it's widely understood and well documented that this is an intricate set of activities our team has already pulled off successfully multiple times, and it simply takes time to get it all operational. The crucial element we're zeroing in on through all of it is finding sites with patients around the globe. These are going to be worldwide studies, and we're looking at every possible way to make them easy for patients to join and to achieve maximum terminal velocity; so getting the first patient in matters a lot, and getting the last patient in may matter even more. That covers that side, and honestly that's among the enjoyable parts of this work. Now for the sickle cell side: the Utrecht study will take up to 10 patients. That team is highly experienced and recognized for their expertise in examining red cell metabolism and in using the oxygen scanner to assess point of sickling and other markers that matter in sickle cell. In that trial, patients begin at 20 milligrams, then can move to 50 milligrams, and afterward up to 100 milligrams. They then remain in the study for a minimum of a year; that contrasts with the NIH study, which was — the NIH study was the initial trial in adults with sickle cell disease, and there they began at 5, 20, 50, and later amended it to 100. So all told, that's 8 weeks of therapy, followed by a taper, and after that, those patients who are both willing and able may enter an extension. So I'd say there are plenty of parallels when it comes to grasping the key endpoints we've discussed, and from each study you gain an impression of both efficacy and safety. With the Utrecht study, I think what you get right away is a bit more insight, as time goes on, into chronic dosing, which is something the NIH study can't quite provide immediately, since those patients receive 8 weeks of treatment. And later on, we'll certainly obtain additional long-term data from the patients who enter the extension, though at this point we don't yet know how many of those patients there will ultimately be. So I'll leave it at that.

Mark Breidenbach

analyst
#23

All right, that's really useful. One more quick question from me. Will the Phase II/III include sites in Africa?

Chris Bowden

executive
#24

Yes.

Danielle Brill

analyst
#25

To start, could you jog our memory on what you're anticipating from an ADCOM meeting, and possibly what you're expecting internally regarding priority review? Then, Darrin, I hoped you could clear up one thing from your prepared remarks—sorry. When you mentioned your market research, was it that 70% of providers are already ordering genetic testing for anemia of unknown etiologies, or that they wish to?

Darrin Miles

executive
#26

I'll take the second question, and then I'll step aside so Chris can handle the first for you. That 70% figure is about the share of physicians routinely ordering additional tests to pursue a more definitive diagnosis for patients diagnosed with hemolytic anemia but of unknown etiology, correct? That means they lean toward ordering either an enzyme test, a genetic test, a genetic panel, or some combination, and some might do so reflexively. The reason I brought up that insight is that it tells us we have a highly receptive audience for Anemia ID and gives us a sense of what further uptake will look like, especially now that more people are out there educating the community about it; so with that, I'll hand things over to Chris.

Chris Bowden

executive
#27

You were asking about priority review as it relates to the Pyruvate kinase deficiency filing, correct?

Danielle Brill

analyst
#28

Yes.

Chris Bowden

executive
#29

Right, so we'll learn what the FDA decides on that one 60 days after we submit. So that ought to land somewhere around August, roughly the middle of the month.

Danielle Brill

analyst
#30

Okay. And I guess...

Chris Bowden

executive
#31

Sorry. We lost you.

Danielle Brill

analyst
#32

How do you view the advisory committee feedback from the meeting?

Chris Bowden

executive
#33

Regarding ADCOM, it's premature to say. At times you receive certain indications ahead of time, but we're still at an early point, so there's no way to know yet.

Jacqualyn Fouse

executive
#34

Thanks, operator, and thanks to all of you for your questions this morning. As we enter a very bright future as a transformed Agios, we're eager to witness a meaningful difference in the lives of patients who have genetically defined diseases, beginning with our possible launch in PK deficiency next year. I want to express my gratitude to my Agios colleagues for their commitment and passion when it comes to making a difference for our patients. I'd also like to thank every patient, caregiver, and physician who works alongside us in so many ways. And today, a special thank-you goes to Chris — we'll be interacting with him more, and I'm sure all of you will too over the next couple of months. We are extremely happy and pleased that he is willing to remain engaged with us at Agios through the end of 2022, at minimum as a strategic advisor, since we'll keep benefiting from his wisdom and insight. So thank you so much, Chris, and we look forward to a few parties over the next couple of months before your next chapter. Thank you, everybody, for joining us today. You may now disconnect. Take care.

Operator

operator
#35

This concludes today's conference call. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.